Literature DB >> 16155930

Cyclophosphamide disposition in an anephric child.

Jeannine S McCune1, Denise Adams, Alan C Homans, Ann Guillot, Lisa Iacono, Clinton F Stewart.   

Abstract

Although limited data are available about cyclophosphamide disposition in patients with renal insufficiency, nothing has been reported in anephric patients. We characterized cyclophosphamide pharmacokinetics in an anephric child with bilateral Wilms tumor, both on (day 1) and off (day 2) hemodialysis. The median cyclophosphamide clearance on and off hemodialysis was 5.34 and 3.82 L/hr*m(2), respectively, demonstrating elimination of cyclophosphamide in this anephric child. The off hemodialysis clearance was similar to that in children with normal renal function. Hydroxycyclophosphamide (HCY) AUC was 20.6 and 8.77 microM*hr on and off hemodialysis. Carboxyethylphosphoramide mustard (CEPM) AUC obtained on hemodialysis (i.e., 194 microM*hr) was similar to that in children with normal renal function, although an elevated CEPM AUC was observed when hemodialysis was not received (i.e., 383 microM*hr). With the recent findings that clinical outcomes are related to CEPM AUC, further data are needed regarding the pharmacokinetics of cyclophosphamide and relevant metabolites in anephric children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16155930     DOI: 10.1002/pbc.20558

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

1.  Medulloblastoma treatment in a child on dialysis.

Authors:  Nadia Puma; Veronica Biassoni; Lorenza Gandola; Emilia Pecori; Gianluigi Ardissino; Fabio Paglialonga; Alice Indini; Manila Antonelli; Maura Massimino
Journal:  CNS Oncol       Date:  2014-01

2.  Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.

Authors:  Jeannine S McCune; David H Salinger; Paolo Vicini; Celeste Oglesby; David K Blough; Julie R Park
Journal:  J Clin Pharmacol       Date:  2008-10-16       Impact factor: 3.126

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.